Agile therapeutics- reaffirmed its previously announced operating expense guidance for full year 2020 to be in range of $52 mln to $56 mln

Agile therapeutics inc - reaffirmed its previously announced operating expense guidance for full year 2020 to be in range of $52 million to $56 million.agile therapeutics inc - reaffirmed its previously announced net revenue guidance for q4 of 2020 to be in range of $1 million to $2 million.agile therapeutics - cash, cash equivalents and marketable securities as of june 30, 2020 will be sufficient through end of 2021.
AGRX Ratings Summary
AGRX Quant Ranking